RecensMedical, Inc. (KOSDAQ:394420)
South Korea · Delayed Price · Currency is KRW 10,250
+490 (5.02%)
At close: Sep 4, 2026
RecensMedical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Revenue | - | 8,829 | 6,259 | 5,771 | 281.76 |
Other Revenue | 0 | - | - | -0 | - |
| 6,521 | 8,829 | 6,259 | 5,771 | 281.76 | |
Revenue Growth | - | 41.05% | 8.47% | 1948.03% | - |
Cost of Revenue | 3,048 | 4,519 | 4,916 | 2,765 | 189.86 |
Gross Profit | 3,472 | 4,309 | 1,343 | 3,006 | 91.91 |
Selling, General & Admin | 11,372 | 10,701 | 10,993 | 12,079 | 17,019 |
Research & Development | 2,887 | 3,410 | 2,422 | 2,836 | 2,867 |
Amortization of Goodwill & Intangibles | 57.27 | 53.33 | 47.46 | 46.11 | 25.81 |
Other Operating Expenses | 190.51 | 151.63 | 103.59 | 80.96 | 119.79 |
Operating Expenses | 15,214 | 14,950 | 15,504 | 15,590 | 20,337 |
Operating Income | -11,742 | -10,640 | -14,161 | -12,584 | -20,245 |
Interest Expense | -182.48 | -2,408 | -3,897 | -3,064 | -2,206 |
Interest & Investment Income | 75.61 | 107.08 | 33.27 | 162.3 | 113.82 |
Currency Exchange Gain (Loss) | 287.3 | -6.28 | 132.5 | 53.29 | 457.5 |
Other Non Operating Income (Expenses) | 520.6 | -6,172 | 10,049 | 7,926 | -19,115 |
EBT Excluding Unusual Items | -11,041 | -19,119 | -7,844 | -7,506 | -40,994 |
Gain (Loss) on Sale of Assets | -4.55 | - | - | -66.17 | - |
Pretax Income | -11,046 | -19,119 | -7,844 | -7,572 | -40,994 |
Net Income | -11,046 | -19,119 | -7,844 | -7,572 | -40,994 |
Net Income to Common | -11,046 | -19,119 | -7,844 | -7,572 | -40,994 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 10 | 7 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 10 | 7 | 3 | 3 | 3 |
Shares Change | - | 93.31% | 3.17% | 0.43% | - |
EPS (Basic) | -1125.66 | -2890.00 | -2292.00 | -2282.91 | -12412.11 |
EPS (Diluted) | -1125.66 | -2890.00 | -2292.00 | -2282.91 | -12412.11 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -12,402 | -9,354 | -10,215 | -13,530 | -22,740 |
Free Cash Flow Per Share | -1263.87 | -1413.99 | -2984.99 | -4079.06 | -6885.21 |
Gross Margin | 53.25% | 48.81% | 21.46% | 52.09% | 32.62% |
Operating Margin | -180.08% | -120.52% | -226.24% | -218.07% | -7185.17% |
Profit Margin | -169.40% | -216.56% | -125.31% | -131.22% | -14549.34% |
Free Cash Flow Margin | -190.19% | -105.95% | -163.20% | -234.47% | -8070.77% |
EBITDA | -11,120 | -10,130 | -13,772 | -12,059 | -19,821 |
EBITDA Margin | -170.54% | -114.75% | -220.03% | -208.98% | - |
D&A For EBITDA | 621.7 | 509.91 | 388.72 | 524.36 | 424.46 |
EBIT | -11,742 | -10,640 | -14,161 | -12,584 | -20,245 |
EBIT Margin | -180.08% | -120.52% | -226.24% | -218.07% | - |
Advertising Expenses | - | 1,436 | 2,081 | 2,007 | 1,008 |